Role of Metabolomics in the Diagnosis of Endometriosis
This trial is active, not recruiting.
|Treatment||laparoscopic surgery, obtainment of biological samples|
|Sponsor||University of Cagliari|
|Start date||December 2014|
|End date||March 2016|
|Trial size||40 participants|
|Trial identifier||NCT02337816, ENDOMETAB01|
Endometriosis is one of the most common benign gynecological, affecting about 10% of premenopausal women. The pathophysiology of this disease is still not completely clear. Despite its prevalence, there is no blood test available for the diagnosis of endometriosis and the average delay time to diagnosis is 9.4 years.
Metabolomics is a scientific discipline that studies changes in metabolites related to the pathophysiology of the disease.
Aim of the study is to identify an alteration in the expression of the metabolites in women with endometriosis
|Intervention model||parallel assignment|
Plasma and urine concentration of metabolites
time frame: At least one month after discontinuation of hormonal therapies , before laparoscopic surgery
Female participants from 18 years up to 45 years old.
Inclusion Criteria: - women of childbearing age ; - written consent to laparoscopic surgery; - written consent to the study . Exclusion Criteria: - Suspicion or diagnosis of malignant disease - Inability or unwillingness to provide written consent
|Official title||Role of Metabolomics in the Diagnosis of Endometriosis|
Call for more information